|
| What are this week’s market risks or opportunities? |
|
|
| April was extraordinary and the reason matters. |
|
| The S&P 500 surged more than 10% — its best month since the pandemic rebound in November 2020. It was driven by two things that arrived at the same time: valuations compressed by March’s war-induced selloff, and the best corporate earnings season in years. |
|
| As of May 7, 82% of S&P 500 companies have beaten EPS estimates, the highest rate since 2021. 81% beat on revenue. These are historically exceptional numbers. |
|
| With NVIDIA still reporting on May 20, the best earnings season in years isn’t over. |
|
|
|
|
|
|
| Which trades should I consider? |
|
|
| Healthcare usually isn’t the most exciting sector in a rally, but while the AI trade dominated headlines, Q1 earnings quietly reminded investors why healthcare belongs in any portfolio. |
|
| Eli Lilly posted revenue growth of 47.4%. AbbVie raised full-year guidance. Johnson & Johnson raised its outlook above $100 billion for the first time in company history. |
|
| The drivers, including drug pipelines, demographic trends, and regulatory cycles have nothing to do with AI capex or rate expectations. That independence is the value. |
|
| When tech multiples get stretched, healthcare’s steady dividends keep paying and the right picks delivered both downside protection and capital gains this year. Defensive doesn’t mean stagnant. |
|
|
|
|
|
|
| Should I consider this trade? |
|
|
| IQVIA (NYSE: IQV) helps pharma and biotech companies run clinical trials and turn healthcare data into business intelligence. It beat Q1 estimates on both revenue ($4.15B, +8.4% YoY) and EPS ($2.90, +7.4%). |
|
| Yet the stock still sits significantly below its 52-week high and every analyst covering it has a price target above the current price. |
|
| ProPicks AI added it to the Healthcare Heroes, Beat the S&P 500 and Top Value Stocks strategies on May 1, four days before the earnings report, and so far it’s up 14.43%. |
|
| Here’s what our AI model saw in IQVIA: A world-class clinical research and data powerhouse, with a $34.2 billion backlog and 19 of the top 20 pharma companies already using its AI agents, all priced as though none of that matters. |
|
| A soft new business pipeline and high debt are keeping some investors cautious. |
|
| But the model doesn’t wait for the market to agree. Whether this is a turning point or a temporary spike, the next few quarters will tell. |
|
|
|
|
|
|
| Data correct to 07.05.2026 |
|
Posts
No comments:
Post a Comment